ChemicalBook > Product Catalog >Pharmaceutical intermediates >Heterocyclic compound >Islatravir

Islatravir

Islatravir Structure
CAS No.
865363-93-5
Chemical Name:
Islatravir
Synonyms
EFdA;E2FDA;Islatravir;Islatravir(MK-8591);MK-8591 (Islatravir);Adenosine Impurity 22;Adenosine Related Compound;2-DEOXY-4-C-ETHYNYL-2-FLUORO-;2'-Deoxy-4'-ethynyl-2-fluoroadenosine;4'-ethynyl-2-fluoro-2'-deoxyadenosine
CBNumber:
CB32657140
Molecular Formula:
C12H12FN5O3
Molecular Weight:
293.25
MOL File:
865363-93-5.mol
Modify Date:
2024/7/2 8:55:06

Islatravir Properties

Melting point 220.0-221.4 °C (decomp)
Boiling point 669.2±65.0 °C(Predicted)
Density 1.72±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO:100.0(Max Conc. mg/mL);341.0(Max Conc. mM)
Water:3.57(Max Conc. mg/mL);12.17(Max Conc. mM)
form A solid
pka 13.11±0.60(Predicted)
color White to off-white
InChI InChI=1S/C12H12FN5O3/c1-2-12(4-19)6(20)3-7(21-12)18-5-15-8-9(14)16-11(13)17-10(8)18/h1,5-7,19-20H,3-4H2,(H2,14,16,17)/t6-,7+,12+/m0/s1
InChIKey IKKXOSBHLYMWAE-QRPMWFLTSA-N
SMILES OC[C@@]1(C#C)O[C@@H](N2C3C(=C(N=C(F)N=3)N)N=C2)C[C@@H]1O

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P280-P301+P312-P302+P352-P305+P351+P338
NFPA 704
0
2 0

Islatravir Chemical Properties,Uses,Production

Description

Islatravir belongs to a group of HIV drugs called nucleoside reverse transcriptase translocation inhibitors (NRTTIs). NRTTIs use several different methods to block an HIV enzyme called reverse transcriptase. By blocking reverse transcriptase, NRTTIs prevent HIV from multiplying and can reduce the amount of HIV in the body. This compound may be effective against certain HIV strains that are resistant to other HIV drugs.

Uses

4'-ethynyl-2-fluoro-2'-deoxyadenosine (Islatravir) is a heterocyclic organic compound and can be used as pharmaceutical intermediates.

Mechanism of action

Islatravir belongs to a group of HIV drugs called nucleoside reverse transcriptase translocation inhibitors (NRTTIs). NRTTIs use several different methods to block an HIV enzyme called reverse transcriptase. By blocking reverse transcriptase, NRTTIs prevent HIV from multiplying and can reduce the amount of HIV in the body. This compound may be effective against certain HIV strains that are resistant to other HIV drugs[1].

Pharmacokinetics

Islatravir is converted intracellularly by endogenous kinases to its active triphosphate (TP) form, islatravir-TP, which has a long intracellular half-life, allowing the potential for various dosing options and regimens. In participants without HIV, single oral doses of islatravir were rapidly absorbed, with peak plasma concentrations attained at ~ 0.5 h, with islatravir demonstrating a half-life of ~ 49–61 h. Peak intracellular islatravir-TP concentrations were attained 6–24 h after islatravir administration, with a half-life of 118–171 h; similar pharmacokinetics have been observed in people living with HIV-1. When administered once daily (QD), oral doses of islatravir resulted in steady-state plasma concentrations at approximately Day 14. At the same time, intracellular islatravir-TP reached a steady state by Day 28 and remained above the concentration threshold associated with antiviral efficacy (0.05 pmol/106 cells) for ~ 30 days following cessation of dosing. In addition, doses as low as 0.25 mg QD produced intracellular islatravir-TP concentrations exceeding the therapeutic concentration threshold on Day 1[1].

References

[1] Randolph P Matthews. “A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.” Clinical Drug Investigation (2021): 629–638.

Islatravir Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 74)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Amadis Chemical Company Limited 571-89925085 China 131980 58 Inquiry
Wuhan Topule Biopharmaceutical Co., Ltd +8618327326525 China 8474 58 Inquiry
NewCan Biotech Limited +86-0571-86912261 +8613735419629 China 9980 58 Inquiry
Henan Tianfu Chemical Co.,Ltd. +86-0371-55170693 +86-19937530512 China 21669 55 Inquiry
Shenzhen Nexconn Pharmatechs Ltd +86-755-89396905 +86-15013857715 China 10312 58 Inquiry
Beijing Ribio Biotech Co.,Ltd 010-62664360 +8613328773880 China 117 58 Inquiry
Yunbio Tech Co.,Ltd. +86-010-60605551 +86-18046518538 China 321 58 Inquiry
BOC Sciences +1-631-485-4226 United States 19553 58 Inquiry
TargetMol Chemicals Inc. +1-781-999-5354 +1-00000000000 United States 19892 58 Inquiry
Finetech Industry Limited +86-27-87465837 +8618971612321 China 9618 58 Inquiry
4'-ethynyl-2-fluoro-2'-deoxyadenosine EFdA 2'-deoxy-4'-C-ethynyl-2-fluoro-Adenosine E2FDA 2'-Deoxy-4'-ethynyl-2-fluoroadenosine 4'-ethynyl-2-fluoro-2'-deoxyadenosine EFDA E2FDA Islatravir Adenosine Related Compound Adenosine Related Compound 6 (MK-8591) (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol Adenosine, 2'-deoxy-4'-C-ethynyl-2-fluoro- Adenosine Impurity 22 4'-ethynyl-2-fluoro-2'-deoxyadenosine/EFDA Islatravir(MK-8591) (2R,3S,5R)-5-(6-amino-2-fluoro-4H-purin-9(5H)-yl)-2-ethynyl-2-(hydroxymethyl)-tetrahydrofuran-3-ol (2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-2-(hydroxymethyl)oxolan-3-ol Human immunodeficiency virus,Inhibitor,Islatravir,MK 8591,inhibit,MK8591,Reverse Transcriptase,HIV MK-8591 (Islatravir) 2-DEOXY-4-C-ETHYNYL-2-FLUORO- 4'-ethynyl-2-fluoro-2'-deoxyadenosine 865363-93-5 C12H12FN5O3